

Robert Piskol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1889262/publications.pdf>

Version: 2024-02-01

13
papers

1,171
citations

759233

12
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

2524
citing authors

#	ARTICLE	IF	CITATIONS
1	A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. <i>Nature</i> , 2017, 543, 676-680.	27.8	587
2	CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	117
3	A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. <i>Nature</i> , 2018, 562, 429-433.	27.8	105
4	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	27.8	64
5	Stem cell plasticity enables hair regeneration following Lgr5+ cell loss. <i>Nature Cell Biology</i> , 2017, 19, 666-676.	10.3	61
6	Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. <i>Nature Communications</i> , 2020, 11, 5551.	12.8	52
7	A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. <i>Nature Chemical Biology</i> , 2018, 14, 582-590.	8.0	50
8	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4431-4442.	7.0	40
9	An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 638-649.	4.1	26
10	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways. <i>Cancer Discovery</i> , 2021, 11, 778-793.	9.4	26
11	MAP4K4 negatively regulates CD8 T cell-mediated antitumor and antiviral immunity. <i>Science Immunology</i> , 2020, 5, .	11.9	18
12	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. <i>Cell Reports</i> , 2022, 38, 110351.	6.4	18
13	Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 974-985.	4.1	5